The estimated Net Worth of Keith Orford is at least $1.48 Million dollars as of 10 November 2021. Mr. Orford owns over 78,190 units of Calithera Biosciences Inc stock worth over $3,305 and over the last 8 years he sold CALA stock worth over $236,447. In addition, he makes $1,241,570 as Chief Medical Officer at Calithera Biosciences Inc.
Keith has made over 13 trades of the Calithera Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 78,190 units of CALA stock worth $68,025 on 10 November 2021.
The largest trade he's ever made was selling 78,190 units of Calithera Biosciences Inc stock on 10 November 2021 worth over $68,025. On average, Keith trades about 6,609 units every 72 days since 2016. As of 10 November 2021 he still owns at least 66,094 units of Calithera Biosciences Inc stock.
You can see the complete history of Mr. Orford stock trades at the bottom of the page.
Keith Orford M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Orford joined Calithera in January 2015 and currently serves as our Chief Medical Officer. Prior to joining Calithera in January 2015, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline (GSK) where he oversaw the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GSK, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) where he completed clinical training in Internal Medicine as well as postdoctoral work studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation. Dr. Orford received his undergraduate, M.D. and Ph.D. degrees from Georgetown University.
As the Chief Medical Officer of Calithera Biosciences Inc, the total compensation of Keith Orford at Calithera Biosciences Inc is $1,241,570. There are 2 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of $2,209,840.
Keith Orford is 48, he's been the Chief Medical Officer of Calithera Biosciences Inc since 2018. There are 16 older and 6 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
Keith's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C.... und Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: